Evidence map›Paper›PMID 38981984›Full record

ArticleInternal and emergency medicine2024

The gut-pancreas axis: investigating the relationship between microbiota metabolites and pancreatic steatosis.

Furkan Kirsoy, Mehmet Yalniz, İbrahim Halil Bahçecioğlu, Hakan Artaş, Semra Türkoğlu, Onur Solmaz, Ahmed Tawheed

Abstract read
PubMed Publisher
In one paragraph

Article in Internal and emergency medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Gut-to-tumor translocation of multidrug-resistantFrontiers in cellular and infection microbiology · 2025
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Furkan KirsoyDepartment of Internal Medicine, Fethi Sekin City Hospital, Elazig, Turkey.
Mehmet YalnizDepartment of Gastroenterology, Faculty of Medicine, Firat University, Elazig, Turkey.
İbrahim Halil BahçecioğluDepartment of Gastroenterology, Faculty of Medicine, Firat University, Elazig, Turkey.
Hakan ArtaşDepartment of Radiology, Faculty of Medicine, Firat University, Elazig, Turkey.
Semra TürkoğluDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Firat University, Elazig, Turkey.
Onur SolmazDepartment of Radiology, Batman Training and Research Hospital, Batman, Turkey.
Ahmed TawheedEndemic Medicine Department, Faculty of Medicine, Helwan University, Ain Helwan, Cairo, 11795, Egypt. ahmed.tawhid@med.helwan.edu.eg.ORCID 0000-0002-9382-8733

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of pancreatic steatosis has increased and it has been linked to the rising prevalence of metabolic syndrome. Metabolic syndrome is known to have a strong connection with changes in intestinal microbiota. The aim of this study was to explore the relationship between pancreatic steatosis and the levels of trimethylamine N-oxide (TMAO) and butyrate. In this study, 136 individuals were randomly selected from outpatient clinics at Firat University Hospital. The study evaluated their demographic characteristics, anthropometric measurements, and biochemical parameters. The presence of pancreatic steatosis was assessed using abdominal ultrasonography. Additionally, the levels of TMAO and butyrate were measured. The mean age of individuals in the study was 44.5 ± 14.6. 84 of the subjects were females. Using the waist circumference, 61 were considered obese and 34 overweight. The detection rate of pancreatic steatosis was found to be 70.6%. The study found that individuals with steatosis had higher average age, presence of hepatic steatosis, BMI, waist circumference measurements, and presence of metabolic syndrome than those without steatosis. A significantly higher butyrate level was detected in those without steatosis (p = 0.001). TMAO levels were slightly higher in patients without steatosis than in those with steatosis; however, this was insignificant. Pancreatic steatosis is highly associated with alterations in levels of microbiota metabolites, indicating a potential role of these metabolites in the pathogenesis of the disease and subsequent therapeutic targets. Several other factors, such as age, hepatic steatosis, diabetes, and waist circumference, have also been identified as potential predictors of pancreatic steatosis.

Indexed as

ButyratesDysbiosisMethylaminesPancreatic DiseasesAdultCase-Control StudiesFemaleHumansMaleMetabolic SyndromeMiddle AgedObesityUltrasonographyYoung AdultButyratesMethylaminestrimethyloxamineButyrateFatty liverFatty pancreasMetabolic syndromeMicrobiotaPancreatic steatosisTrimethylamine N-oxide

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.